Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants - Wikidata - awgldk - TriplyDB

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants

http://www.wikidata.org/entity/Q30557549

about

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.Type 1 diabetes mellitus.An Islet-Targeted Genome-Wide Association Scan Identifies Novel Genes Implicated in Cytokine-Mediated Islet Stress in Type 2 Diabetes.Stress-induced dissociations between intracellular calcium signaling and insulin secretion in pancreatic islets Experimental evaluation and computational modeling of the effects of encapsulation on the time-profile of glucose-stimulated insulin release of pancreatic islets.From immunobiology to β-cell biology: the changing perspective on type 1 diabetes Reduced β-cell function in early preclinical type 1 diabetes Following the fate of the failing β-cell: new insights from first-phase insulin responses Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray.Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?Staging the progression to type 1 diabetes with prediagnostic markers Dysregulation of glucose metabolism in preclinical type 1 diabetes.Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes.Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis.β-Cell mass versus function in type 1 diabetes mellitus: truth or dare?Glucose-stimulated insulin release: Parallel perifusion studies of free and hydrogel encapsulated human pancreatic islets.Autoreactive T cells in type 1 diabetes.Aetiology of type 1 diabetes: Physiological growth in children affects disease progression.Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges.Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.Class II HLA Genotype Association with First Phase Insulin Response Is Explained by Islet Autoantibodies.The impact of probiotics' administration on glycemic control, body composition, gut microbiome, mitochondria, and other hormonal signals in adolescents with prediabetes - A randomized, controlled trial study protocol.β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis

P2860

Q27334999-1D1F3965-B4B9-486A-B107-C2D6B78A7A43 Q30235021-A7712C0F-13B9-43EA-971E-DEDC7FBBBAFF Q30279270-435A872E-F461-42C6-99E3-24D341D2CAE3 Q30300205-8D40B787-6665-476A-B642-5082CD85994E Q30641716-9966564F-FFDB-4745-84FF-640BDF01A029 Q36124036-7ED699AE-036E-42E6-9533-0D1C65532F8F Q36461183-18AF014D-4322-458C-AF63-8CBCAA8ADD5D Q37333539-5AA0196B-E16F-4CF3-88A0-6556C40850B3 Q37659402-47798EBD-8ED8-4A36-ABD0-F64282965CB8 Q38365047-31B1244A-1A1D-4EAF-951B-3B91791A6168 Q38607498-63E1FE03-E113-4F52-A0BE-36EC6AAC7F6C Q38846782-D0923C4A-7576-4AEA-A4F2-A26299A70BF9 Q38895409-1C2DDF6C-E155-41F0-8D13-52B9D7F718B0 Q39040207-A2B2BAF5-1788-4BDD-A15D-9C4F79804FE5 Q39593898-08294C6F-77C8-4871-AA35-3B3739C0EF37 Q41689680-B50E96D5-158B-44C3-82DB-19C38DC28535 Q46751998-8556F5B4-F6F3-4CC3-A113-C2D142D5ADB6 Q47725669-C4E06DBD-6A79-486A-919E-C09AA8E6995B Q48004838-77E987B3-9F4D-473A-B5DF-F5B85428805C Q48103893-CB48F2F8-0C61-43EC-9F34-FD8B0433B72A Q48123950-DF7E2902-AAAF-4EAA-ABFB-DC66DC5A1BC8 Q48144667-09A5B21D-75D8-4979-A714-4B7284A30B51 Q49110588-BC454969-B13A-4670-8E9C-9B17D80F9646 Q50120159-F1EAA2D2-ABB1-4680-AA09-09075C630167 Q55646945-26DC97B9-17DE-4508-B011-CBE4FF8FD4C5 Q58792346-74F8CA52-2360-4E0C-83A5-3385E42F6AC8

P2860

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants

http://www.wikidata.org/entity/Q30557549

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Acceleration of the loss of th ...... tion trial-type 1 participants

@ast

Acceleration of the loss of th ...... tion trial-type 1 participants

@en

type

label

Acceleration of the loss of th ...... tion trial-type 1 participants

@ast

Acceleration of the loss of th ...... tion trial-type 1 participants

@en

prefLabel

Acceleration of the loss of th ...... tion trial-type 1 participants

@ast

Acceleration of the loss of th ...... tion trial-type 1 participants

@en

P1433

Q30557549-2FB07F90-FEBE-4F83-9C11-11966EACC72E

P1476

Q30557549-99CB3E47-1D35-4976-B985-451FB1CAACE9

P2093

Q30557549-094B09AA-3234-480F-9C2F-60BA3F7B8060

Q30557549-1A0D5F0B-EDA7-48FD-AA8C-9DDD4E2E156D

Q30557549-346CE7E1-041B-465C-B912-048517B21A48

Q30557549-485140B4-48F8-457A-BE1B-664AAD748176

Q30557549-5A4337D9-2C17-40BF-937F-3699903024E4

Q30557549-64687A19-6580-4A7E-9127-62055000B935

Q30557549-794D4D08-B448-4B32-B223-FBEC74539479

Q30557549-7A9EC94D-E1C6-4621-A0E4-0F37FBD7FEE4

Q30557549-8BA17736-0664-4784-BA0D-9878B3261765

Q30557549-8CD64313-1CDF-42E3-B999-BD0A85A59CFD

P2860

Q30557549-1C64E861-4970-4C74-B84E-BF4B3D94DFDA

Q30557549-1C954209-E9B3-462D-A3C5-48628DB43FA2

Q30557549-235591B8-45EF-4FB8-B645-B3AE86E45884

Q30557549-45942452-E2E5-4CFB-B475-40C361864595

Q30557549-637B4952-AE3D-4B4F-8CE1-419DBE6388D2

Q30557549-7B96F221-10F2-4750-B183-128CCFC3797C

Q30557549-92D22E2A-7E5D-4F46-9CAB-247464506DE5

Q30557549-C2B7D7A1-13C2-4355-8BA6-DC127CDBDAC4

Q30557549-C6DBF5E5-3A24-405F-9621-A45BD4FA6252

Q30557549-C8282B70-5C43-4676-A3CE-549902E49D4A

P304

Q30557549-8D36B053-1ECE-4876-91A3-AA8BE31C9718

P31

Q30557549-37BB7FE4-2858-4993-827D-F92A45506A98

P356

Q30557549-3C1DC9A6-C4C7-4CA5-87DA-880303188189

P407

Q30557549-54218121-3345-4D4C-9986-D295E43FF920

P433

Q30557549-252BC266-F16F-4235-B149-34860DFC23C8

P478

Q30557549-2A52F562-5DAA-471A-B2A6-083BAFF140E0

P577

Q30557549-83D4A8EC-1A01-4ABC-BFC2-2C3EE02716C8

P5875

Q30557549-06CD3CFD-3DFF-45C4-9B6C-09046796140D

P698

Q30557549-4706E605-9BE8-4C12-A50F-993A4CEBABFD

P921

Q30557549-C109008E-8AF2-477F-98F5-2B9AED3B43C8

P932

Q30557549-60A66112-A74C-4F1E-A7BC-3C7C140E084B

P356

P1433

P1476

Acceleration of the loss of th ...... tion trial-type 1 participants

@en

P2093

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Craig A Beam

http://www.w3.org/2001/XMLSchema#string

Della Matheson

http://www.w3.org/2001/XMLSchema#string

Jay M Sosenko

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jeffrey Mahon

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Krischer

http://www.w3.org/2001/XMLSchema#string

Jerry P Palmer

http://www.w3.org/2001/XMLSchema#string

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Lisa E Rafkin

http://www.w3.org/2001/XMLSchema#string

P2860

Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset

Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset.

Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population.

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients.

First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion.

Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

P304

4179-4183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB13-0656

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044325

http://www.w3.org/2001/XMLSchema#string

P698

23863814

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3837047

http://www.w3.org/2001/XMLSchema#string